Maneesh Sud1, Navdeep Tangri2, Adeera Levin3, Melania Pintilie4, Andrew S Levey5, David M Naimark6. 1. Department of Medicine, University of Toronto, Toronto, Ontario, Canada. 2. Division of Nephrology, Seven Oaks General Hospital, University of Manitoba, Winnipeg, Manitoba, Canada. 3. Division of Nephrology, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada. 4. Department of Biostatistics, University Health Network, Toronto, Ontario, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. 5. Division of Nephrology, Tufts Medical Center, Boston, MA. 6. Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada; Division of Nephrology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Institute of Health Policy Management and Evaluation, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: david.naimark@sunnybrook.ca.
Abstract
BACKGROUND: Patients with chronic kidney disease (CKD) stages 3-5 are at increased risk of progressing to end-stage renal disease (ESRD) or dying prior to the development of ESRD compared with patients with less severe CKD. The magnitude of these risks may vary by stage, which has important implications for therapy. Our objective was to apply a competing risk analysis in order to estimate these risks in a referred cohort of patients with CKD by stage at referral and identify risk factors associated with each outcome. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: 3,273 patients with CKD stages 3-5 who were referred to the nephrology clinic at Sunnybrook Health Sciences Centre, Toronto, prior to December 31, 2008, with follow-up data available prior to December 31,2008. PREDICTORS: CKD stage at time of referral; demographic, laboratory, and clinical characteristics. OUTCOMES: ESRD, defined as the initiation of dialysis therapy or pre-emptive kidney transplantation, and death from any cause prior to ESRD. MEASUREMENTS: Baseline laboratory data. RESULTS: Over a median follow-up of 2.98 years, 459 patients (14%) developed ESRD and 540 (16%) died. Rates per 100 patient-years of ESRD versus death prior to ESRD for CKD stage 3A were 0.6 (95% CI, 0.1-1.0) versus 2.2 (95% CI, 1.2-3.1; P<0.001); for CKD stage 3B, 1.4 (95% CI, 0.8-2.1) versus 4.4 (95% CI, 3.3-5.6; P<0.001); for CKD stage 4, 7.7 (95% CI, 5.9-9.4) versus 8.0 (95% CI, 6.2-9.8; P=0.6); and for CKD stage 5, 41.4 (95% CI, 34.4-48.4) versus 9.4 (95% CI, 5.2-13.4; P<0.001). For those with CKD stage 4, we identified 12 variables associated with higher risk of ESRD and 7 variables associated with higher risk of death prior to ESRD. LIMITATIONS: A cohort analyzed retrospectively. CONCLUSIONS: ESRD and death prior to ESRD incidence was most similar in CKD stage 4. We identified variables easily assessed at the time of referral that could discriminate between these risks.
BACKGROUND:Patients with chronic kidney disease (CKD) stages 3-5 are at increased risk of progressing to end-stage renal disease (ESRD) or dying prior to the development of ESRD compared with patients with less severe CKD. The magnitude of these risks may vary by stage, which has important implications for therapy. Our objective was to apply a competing risk analysis in order to estimate these risks in a referred cohort of patients with CKD by stage at referral and identify risk factors associated with each outcome. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: 3,273 patients with CKD stages 3-5 who were referred to the nephrology clinic at Sunnybrook Health Sciences Centre, Toronto, prior to December 31, 2008, with follow-up data available prior to December 31,2008. PREDICTORS: CKD stage at time of referral; demographic, laboratory, and clinical characteristics. OUTCOMES: ESRD, defined as the initiation of dialysis therapy or pre-emptive kidney transplantation, and death from any cause prior to ESRD. MEASUREMENTS: Baseline laboratory data. RESULTS: Over a median follow-up of 2.98 years, 459 patients (14%) developed ESRD and 540 (16%) died. Rates per 100 patient-years of ESRD versus death prior to ESRD for CKD stage 3A were 0.6 (95% CI, 0.1-1.0) versus 2.2 (95% CI, 1.2-3.1; P<0.001); for CKD stage 3B, 1.4 (95% CI, 0.8-2.1) versus 4.4 (95% CI, 3.3-5.6; P<0.001); for CKD stage 4, 7.7 (95% CI, 5.9-9.4) versus 8.0 (95% CI, 6.2-9.8; P=0.6); and for CKD stage 5, 41.4 (95% CI, 34.4-48.4) versus 9.4 (95% CI, 5.2-13.4; P<0.001). For those with CKD stage 4, we identified 12 variables associated with higher risk of ESRD and 7 variables associated with higher risk of death prior to ESRD. LIMITATIONS: A cohort analyzed retrospectively. CONCLUSIONS:ESRD and death prior to ESRD incidence was most similar in CKD stage 4. We identified variables easily assessed at the time of referral that could discriminate between these risks.
Authors: Anima Singh; Girish Nadkarni; Omri Gottesman; Stephen B Ellis; Erwin P Bottinger; John V Guttag Journal: J Biomed Inform Date: 2014-11-15 Impact factor: 6.317
Authors: Joshua Lang; Ronit Katz; Joachim H Ix; Orlando M Gutierrez; Carmen A Peralta; Chirag R Parikh; Suzanne Satterfield; Snezana Petrovic; Prasad Devarajan; Michael Bennett; Linda F Fried; Steven R Cummings; Mark J Sarnak; Michael G Shlipak Journal: Nephrol Dial Transplant Date: 2018-06-01 Impact factor: 5.992
Authors: Maneesh Sud; Navdeep Tangri; Melania Pintilie; Andrew S Levey; David M J Naimark Journal: J Am Soc Nephrol Date: 2014-09-04 Impact factor: 10.121
Authors: Mark D Jesky; Mary Dutton; Indranil Dasgupta; Punit Yadav; Khai Ping Ng; Anthony Fenton; Derek Kyte; Charles J Ferro; Melanie Calvert; Paul Cockwell; Stephanie J Stringer Journal: PLoS One Date: 2016-11-10 Impact factor: 3.240
Authors: Robert Provenzano; Anatole Besarab; Chao H Sun; Susan A Diamond; John H Durham; Jose L Cangiano; Joseph R Aiello; James E Novak; Tyson Lee; Robert Leong; Brian K Roberts; Khalil G Saikali; Stefan Hemmerich; Lynda A Szczech; Kin-Hung Peony Yu; Thomas B Neff Journal: Clin J Am Soc Nephrol Date: 2016-04-19 Impact factor: 8.237
Authors: Aghogho Odudu; Mohamed Tarek Eldehni; Gerry P McCann; Mark A Horsfield; Tobias Breidthardt; Christopher W McIntyre Journal: Eur Radiol Date: 2015-12-17 Impact factor: 5.315
Authors: Elaine Amaral de Paula; Mônica Barros Costa; Fernando Antonio Basile Colugnati; Rita Maria Rodrigues Bastos; Chislene Pereira Vanelli; Christiane Chaves Augusto Leite; Márcio Santos Caminhas; Rogério Baumgratz de Paula Journal: Rev Lat Am Enfermagem Date: 2016-09-09